Article and Video CATEGORIES
Dr. Mehta is a 2018 Seattle Met Top Doctor Award winner. He enjoys working with patients and family members. There are a wide variety of treatment options available for nearly every patient, so it is important to spend as much time as is needed in order to weight the benefits and risks to any particular approach. He feels that it is important that communication is open and honest. The goals of treatment, whether it is going for cure or maximizing quality of life should be openly discussed and re-discussed as the need arises. For more about Dr.
Dr. Vivek Mehta, Radiation Oncologist at Swedish Cancer Institute in Seattle, WA, provides a historical perspective of radiation therapy as it transitions to a more targeted treatment approach.
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Hello Linda, my name is Alexandra Beneke, I'm the Outreach Manager for GRACE. Your willingness to share your experiences and knowledge with the cancer community is truly inspiring. Your dedication to...
Recent Comments
That's…